<DOC>
	<DOCNO>NCT02010099</DOCNO>
	<brief_summary>Eligible patient bleed hemorrhoid grade 2-3 randomized test-1 product ( PP110 Gel ) , test-2 product ( PP-110 medicate wipe ) control ( Preparation-H cream ) . Test product usage : daily , 1-5 minute prior first bowel movement . Control product usage : accord label , 3-4 time daily application rectal region . At end day , subject fill questionnaire regard bleeding , pain , discharge , swell , itch , discomfort painkiller usage . Treatment two week , subject fill feedback questionnaire address treatment efficacy subject satisfaction . Also , end two week , subject examine study physician assess hemorrhoid severity .</brief_summary>
	<brief_title>A Prospective , Randomized , Three Arms , Open Label Study Comparing Safety Efficacy Two Formulations PP110 Active Comparator Preparation-HÂ® Cream Treatment Bleeding Hemorrhoids Grades 2-3</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemorrhoids</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Petrolatum</mesh_term>
	<mesh_term>Pramoxine</mesh_term>
	<criteria>1 . Age 1870 2 . Bleeding hemorrhoid / without pain 3 . Diagnosis internal hemorrhoid grade 23 , external bleeding hemorrhoid 4 . Signed Informed Consent 1 . Known rectal sensitivity 2 . Rectal infection 3 . Grade IV hemorrhoid 4 . Use anticoagulant ( except Aspirin Plavix ) within 30 day prior enrollment 5 . Known inflammatory bowel disease 6 . Anal fissure 7 . Military personnel 8 . Female patient pregnant , use reliable method birth control , nurse 9 . Patients involve another experimental trial within past 30 day 10 . Patients presently diagnose cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>